Lv3
290 积分 2024-05-12 加入
Prolonged time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery is related to unimproved pathological response and poor survival prognosis for esophageal squamous cell carcinoma
5天前
已完结
Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study
2个月前
已完结
O-6 EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study
3个月前
已完结
Efficacy of Pd-1/Pd-L1 Inhibitors in Advanced Gastroesophageal Cancer Based on Characteristics: A Meta-Analysis
3个月前
已关闭
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
4个月前
已完结
Short-term Outcomes of Adjuvant Nivolumab After Neoadjuvant Chemotherapy in Patients With Resected Esophageal Squamous Cell Carcinoma
4个月前
已完结
Cancer immunotherapy responses persist after lymph node resection
4个月前
已完结
The association between fatty acid intake and breast cancer based on the NHANES and Mendelian randomization study
4个月前
已完结
Combined influence of nutritional and inflammatory status and depressive symptoms on mortality among US cancer survivors: Findings from the NHANES
4个月前
已完结
Efficacy and safety of neoadjuvant chemotherapy combined with PD-1 antibody for esophageal squamous cell carcinoma in the real world
4个月前
已完结
皖公网安备34019202002308
